dengue fever

dengue fever
Name	Dengue fever
Icd10	A90
Icd9	061
Medlineplus	000104

dengue fever

Dengue fever is an acute mosquito-borne viral illness caused by four antigenically distinct serotypes of dengue virus. It produces a spectrum of disease ranging from mild febrile illness to severe plasma leakage, bleeding, and organ impairment, and it is a major public health challenge across tropical and subtropical regions. Large-scale outbreaks have involved populations in Asia, the Americas, Africa, and the Pacific, generating coordinated responses from agencies and research institutions.

Introduction

Dengue fever emerged as a recognized public health problem in the 20th century with epidemics reported in Manila, Hawaii, São Paulo, Bangkok, and Jakarta; modern surveillance and control involve organizations such as the World Health Organization, Centers for Disease Control and Prevention, and national ministries of health. The etiologic agents are single-stranded RNA viruses of the genus Flavivirus within the family Flaviviridae, sharing lineage with Zika virus, West Nile virus, Yellow fever virus, and Japanese encephalitis virus. Globalization, urbanization in megacities like Mumbai and Lagos, international travel through hubs such as Singapore Changi Airport and Hartsfield–Jackson Atlanta International Airport, and climate variability influence vector populations and transmission dynamics studied by research centers including the Pasteur Institute and Walter Reed Army Institute of Research.

Signs and symptoms

The typical presentation begins after an incubation period and commonly includes high fever, severe headache, retro-orbital pain, myalgia, and arthralgia, frequently described during outbreaks in Rio de Janeiro and Manila. Rashes and leukopenia are observed in patients treated at tertiary hospitals like Mayo Clinic and Johns Hopkins Hospital; severe forms may progress to plasma leakage, hypovolemic shock, and hemorrhagic manifestations documented in cohorts from Bangladesh and Thailand. Clinical severity classification systems used in clinical trials at institutions such as Oxford University Clinical Research Unit and Mahidol University guide management and triage during mass-casualty scenarios.

Cause and pathophysiology

Dengue viruses (DENV-1 to DENV-4) are transmitted primarily by the peridomestic mosquito Aedes aegypti and, to a lesser extent, Aedes albopictus, vectors studied in entomology programs at London School of Hygiene and Tropical Medicine and University of California, Davis. Viral entry involves receptor-mediated endocytosis with subsequent replication in dendritic cells and hepatocytes, triggering innate and adaptive immune responses characterized in immunology labs at Harvard Medical School and Stanford University School of Medicine. Antibody-dependent enhancement, a process implicated in increased severity during secondary heterologous infections, has been investigated by teams at National Institutes of Health and the European Centre for Disease Prevention and Control. Vascular permeability and coagulopathy result from cytokine storm phenomena elucidated in translational research at Imperial College London and Karolinska Institutet.

Diagnosis

Diagnosis relies on clinical assessment supported by laboratory testing available through reference laboratories such as the Centers for Disease Control and Prevention and the Public Health Agency of Canada. Direct detection methods include virus isolation and nucleic acid amplification tests used in diagnostic centers at CDC Dengue Branch and Institut Pasteur; antigen detection (NS1) assays and serology (IgM, IgG) are performed in hospital laboratories like Singapore General Hospital and Mount Sinai Hospital. Differential diagnosis includes infections managed at global health centers such as Médecins Sans Frontières clinics where clinicians must distinguish dengue from malaria, chikungunya, Zika virus infection, and leptospirosis.

Prevention and control

Prevention strategies combine vector control interventions promoted by World Health Organization programs, community engagement campaigns employed by municipal authorities in cities like Bangkok and Rio de Janeiro, and vaccine deployment evaluated in trials coordinated by organizations such as Sanofi Pasteur, Takeda Pharmaceutical Company, and the Butantan Institute. Vector control tactics include source reduction, insecticide application, and novel approaches like Wolbachia-infected mosquito releases pioneered in projects by Eliminate Dengue and field trials supported by Oxitec. International travel advisories and port health measures from agencies including European Centre for Disease Prevention and Control and U.S. Department of State inform travelers to endemic regions.

Treatment and prognosis

Treatment is largely supportive and delivered in clinical settings ranging from primary care clinics to intensive care units at facilities like Beth Israel Deaconess Medical Center and Royal Brisbane Hospital. Fluid management protocols and hemodynamic monitoring developed in trials at University of Oxford and Johns Hopkins University reduce mortality in severe cases. Blood product transfusion and critical care interventions are used for hemorrhagic complications in tertiary centers such as Groote Schuur Hospital and Charité – Universitätsmedizin Berlin. Prognosis varies by age, comorbidity, access to care, and prior immunity; large cohort studies from Cuba, Sri Lanka, and Puerto Rico have informed risk stratification and public health policy.

Category:Viral diseases